Multipoint left ventricular pacing effects on hemodynamic parameters and functional status: HUMVEE single-arm

Christos-Konstantinos Antoniou1, Polychronis Dilaveris1, Christina Chrysohoou1

  • 1First Department of Cardiology, National and Kapodistrian University of Athens, Hippokrateion General Hospital, Athens, Greece.

Insights

Optimized multipoint pacing (MPP) significantly improved heart failure outcomes compared to cardiac resynchronization therapy (CRT). MPP enhanced exercise capacity, reduced heart failure symptoms, and improved echocardiographic measures, particularly in men with reduced ejection fraction.

Area of Science:

  • Cardiology
  • Biomedical Engineering

Background:

  • Heart failure (HF) with dyssynchrony poses significant challenges.
  • Cardiac resynchronization therapy (CRT) is a standard treatment, but optimization is key.
  • Multipoint pacing (MPP) offers an alternative pacing strategy.

Purpose of the Study:

  • To compare the efficacy of optimized MPP versus optimized CRT in patients with dyssynchronous HF.
  • To evaluate clinical, functional, and echocardiographic improvements.

Main Methods:

  • A single-arm clinical trial involving 80 HF patients.
  • Patients received sequential optimized CRT and optimized MPP over 6- and 12-month periods.
  • Assessments included clinical, laboratory, and echocardiographic parameters at baseline and after each intervention.

Main Results:

  • Optimized MPP demonstrated significant additive benefits over optimized CRT.
  • Improvements were observed in 6-minute walking distance, NYHA class, VTIlvot, stroke volume, LVEF, left atrial volume, pulmonary artery systolic pressure, and right ventricular strain.
  • Benefits were more pronounced in men and patients with lower LVEF, suggesting enhanced depolarization with MPP.

Conclusions:

  • Optimized MPP is superior to optimized CRT in improving hemodynamic parameters and ventricular function in HF patients.
  • MPP offers a promising alternative for patients with dyssynchronous HF, particularly those with reduced LVEF.
  • The study highlights the potential of MPP to achieve more homogeneous ventricular depolarization.
Abstract

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
926
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
83
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
181
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
139